Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies

Richard S. Finn; Kangsheng Gu; Xi Chen; Philippe Merle; Kyung-Hun Lee; Mohamed Bouattour; Peiguo Cao; Wei Wang; Ann‐Lii Cheng; Liangjun Zhu; Ho Yeong Lim; Masatoshi Kudo; Yueyin Pan; Ting‐Tsung Chang; Julien Edeline; Wei Li; Ping Yang; Chen Li; Jianfeng Li; Abby B. Siegel; Shukui Qin

doi:10.1016/j.jhepr.2025.101350

Related publications

Article2022

Abstract CT222: Pembrolizumab (pembro) for previously treated advanced hepatocellular carcinoma (aHCC): Meta-analysis of the phase 3 KEYNOTE-240 and KEYNOTE-394 studies

Richard S. Finn, Kangsheng Gu, Xi Chen, Philippe Merle, Kyung-Hun Lee, Mohamed Bouattour, Peiguo Cao, Wei Wang, Ann‐Lii Cheng, Liangjun Zhu, Ho Yeong Lim, Masatoshi Kudo, Yueyin Pan, Ting‐Tsung Chang, Julien Edeline, Wei Li, Ping Yang, Chen Li, Jianfeng Li, Abby B. Siegel, Shukui Qin

Article2017

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

Richard S. Finn, Stephen L. Chan, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, Abby B. Siegel, Oliver Bautista, P.A. Watson, Masatoshi Kudo

Article2017

Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.

Richard S. Finn, Stephen L. Chan, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, Abby B. Siegel, Oliver Bautista, Masatoshi Kudo

Article2023

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial

Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann‐Lii Cheng, Stephen L. Chan, T.W.C. Yau, Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martínez‐Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn

Article2019

Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho-Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng